Elite Capital is a venture capital / private equity firm with focus on innovative companies with high growth potential in healthcare industry. We have both RMB fund, which invest in domestic projects, and USD fund, in international market.
Historically, Elite Capital USD Fund had invested in innovative U.S. Medtech and Biopharma companies with strong U.S. and China market opportunities. In addition to providing capital, we provide additional services to quickly adapt to local business environment. Our value added services range from recruiting project management team, supervising clinical trials, managing regulatory filing, providing approval guidance, constructing strategic plan and conducting business development.
Elite Capital RMB Fund invests Chinese domestic companies in healthcare industry. We invest in companies at pre IPO stage, as well as companies in earlier stages with strong product portfolio and high growth potential. The RMB fund also provides capital to incubate projects with breakthrough technologies and products from overseas in China.
Elite Capital differentiates itself with two advantages: broad and in-depth network relationships in the healthcare industry and profound know-how throughout the value chain of industry. Our senior team members are former senior executives of pharmaceutical and other healthcare industry companies. Their resources and experiences give them major advantages in identifying products and technologies with great potential value. Their profound knowledge in the industry allows them to put a product in the context of economic environment, regulatory compliance, and market dynamics to assure best chance for product’s commercial success.
Elite Capital’s investments are sourced via our sister company Elite Consulting’s (www.bjelite.com) clientele base (1,500+ companies). In the U.S., Elite Capital had collaborated with Domain Associates, a leading U.S. biomedical venture fund that has invested nearly $3 billion over 30 years in 250 innovative pharmaceutical and med-tech companies.
Dihon Pharma (2010-2014), 4.7x return, exit by M&A to Bayer AG ($586M exit price). Co-invested with Hony Capital. Elite also provided commercial due diligence, executive placement for Sales and Marketing, and corporate strategic planning process.
SMART Medical (2014-), co-invested with Domain Associate ticket size $6.5M. This Israeli company develops innovative products in gastrointestinal endoscopy. Elite Capital provides additional service in handling the Chinese regulatory affairs on behalf of SMART Medical.
Sequent Medical (2014-2017), 3.7x return, exit by M&A to Terumo ($380M exit price). Invested in China products rights (2014, $4M co-investment with Domain Associates) and last round of equity financing (2017, $3M). Elite Capital provided additional service in managing Chinese regulatory affairs for Sequent's innovative catheter-based neurovascular technologies.
Baiyang Pharma (2015-), ticket size $80M Elite Capital lead the investment with co-investors including Sequoia Capital, Highlight Capital and Legend Capital.
32 years of senior executive experience in China pharmaceutical industry. Leadership positions in China medical & regulatory affairs at Novartis, Sanofi, J&J, and Livson. At Elite, Ten years of financial advisory in pharmaceutical and medtech industry, 15 years of experience in management consulting to the China pharmaceutical industry.
Over 27 years of experience in marketing management, strategy consulting and market research in China pharmaceutical industry. Led and participated in nearly one hundred projects, focusing on China growth strategy, opportunity assessment and commercial due diligence. Has worked as a consultant with top multinational companies, including Novartis, Roche and Bayer, as well as top PE investors, including Blackstone, Morgan Stanley and the Carlyle Group
Wright State University USA,MBA and master's degree in economics,The executive chairman of Healthcare Data Industry Alliance in CSER,Vice Chairman of Health Service Industry Development and Reform Alliance.Founding partner of Hao He Group,10+ years of experience in the financial field of Wall Street, with extensive international financial network resources, and an expert of capital operation and industry integration.After returning to China, he founded the largest domestic TPA service company, Beijing Peihe Health Technology Co., Ltd., that was merged into a large domestic A-share pharmaceutical company in 2015. After that he built a leading comprehensive hospital service platform in China.
BS in Economics, Central University of Finance and Economics(CUFE),EMBA, Guanghua School of Management of Peking University.As founding member and general manager of Beijing Vision Capital Co., Ltd.(BVCC), Mr. Chen had spent over 15 years to lead BVCC，focusing on natural resources industry and health industry. BVCC has invested over 1 billion yuan(RMB) in : Guotai Semiconductor、Huayuan Mining、Meridian Mining、Anjin Medical and Beijing Yuho Hospital etc.Before joined BVCC , Mr. Chen served in several big Chinese financial firms: CPIC Securities、Great wall Securities、China Merchant Securities(CMS), and earned rich experience in IPO underwriting、fund management and M&A consulting.
17 years of experience in China as a healthcare executive and pharmaceutical industry consultant. President Asia Pacific for First Databank (Hearst Corp); Corporate Executive for UnitedHealthcare International (Hong Kong). 15 years of experience in pharmaceutical and medical device marketing research and management consulting (The Wilkerson Group, New York; Strategic Marketing Asia Beijing). Nine years biomedical M&A financial advisory (Elite Capital Advisors).
Veteran of 30 years in Healthcare industry, Dr. Li practiced clinical medicine in the U.S. for ten years. Then he spent next ten years as an entrepreneur to develop biopharmaceutics and commercialized a subunit flu vaccine and a recombinant protein drug in China. He then moved to private equity investment for the last ten years with enriched experience in healthcare industry. His expertise is in health service and biopharma with particular interest in mergers and acquisitions.
Served as Head of the Chemical Drug Review Department of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration, and was a long-time contributor to the research and formulation of national drug registration and regulatory policies, as well as the technical evaluation and management of drug marketing licenses. Previous industry experiences include Vice President and Director of R&D center for Fosun, and former CEO of NMS Group in Italy. PhD in Pharmaceutical Chemistry from China Pharmaceutical University.
29 years of senior executive experience in China. As Founder/CEO of BabyCare Ltd. in Beijing (sold to USANA, NYSE:USNA), grew China business from zero to $350M revenue and 250,000 distributors. Founder of Yaolan.com, a leading parenting Internet media company with 12 million active registered users. Prior was Managing Director Wella China (haircare); Sales & Marketing Director SmithKline China (GSK); Vice Chair of AmCham China (American Chamber of Commerce); YPO (Young Presidents Organization) Beijing Chapter Chair
Fenghui (Daniel) Guo
Over 20 years of experiences in product valuation, financing, and acquisition/ merger with focus on medical devices and pharmaceutical industries. Master’s degree from Peking Union Medical College; MBA and a MS in biomedical from Purdue university. Previously worked with Capital One, and Wells Fargo for over 10 years. Founded First Horizon in 2015 and has successfully introduced over 10 medical products to China during the past 5 years
Ten years of experience in China pharmaceutical industry, led and participated in various projects focusing on China opportunity assessment, product valuation, commercial due diligence, and China entry strategy. Expertise in helping overseas pharmaceutical and medtech companies enter China. Master’s degree in Administration (Healthcare) from the University of South Dakota and Bachelor’s degree in Communication from University of California, San Diego.